S&P 500   4,392.93 (-1.13%)
DOW   34,614.26 (-0.73%)
QQQ   365.06 (-1.43%)
AAPL   143.10 (-1.56%)
MSFT   289.48 (-1.59%)
FB   347.50 (-1.72%)
GOOGL   2,770.14 (-1.82%)
TSLA   788.95 (-0.30%)
AMZN   3,346.62 (-1.74%)
NVDA   211.70 (-2.26%)
BABA   151.37 (+0.79%)
NIO   36.70 (-0.19%)
CGC   14.71 (+0.00%)
GE   105.81 (+0.44%)
MU   74.22 (-1.28%)
AMD   106.27 (-1.75%)
T   27.66 (+0.95%)
F   14.56 (+2.82%)
ACB   6.47 (+1.25%)
DIS   177.15 (-0.62%)
PFE   42.68 (-2.04%)
BA   223.72 (-0.20%)
AMC   38.26 (-2.65%)
S&P 500   4,392.93 (-1.13%)
DOW   34,614.26 (-0.73%)
QQQ   365.06 (-1.43%)
AAPL   143.10 (-1.56%)
MSFT   289.48 (-1.59%)
FB   347.50 (-1.72%)
GOOGL   2,770.14 (-1.82%)
TSLA   788.95 (-0.30%)
AMZN   3,346.62 (-1.74%)
NVDA   211.70 (-2.26%)
BABA   151.37 (+0.79%)
NIO   36.70 (-0.19%)
CGC   14.71 (+0.00%)
GE   105.81 (+0.44%)
MU   74.22 (-1.28%)
AMD   106.27 (-1.75%)
T   27.66 (+0.95%)
F   14.56 (+2.82%)
ACB   6.47 (+1.25%)
DIS   177.15 (-0.62%)
PFE   42.68 (-2.04%)
BA   223.72 (-0.20%)
AMC   38.26 (-2.65%)
S&P 500   4,392.93 (-1.13%)
DOW   34,614.26 (-0.73%)
QQQ   365.06 (-1.43%)
AAPL   143.10 (-1.56%)
MSFT   289.48 (-1.59%)
FB   347.50 (-1.72%)
GOOGL   2,770.14 (-1.82%)
TSLA   788.95 (-0.30%)
AMZN   3,346.62 (-1.74%)
NVDA   211.70 (-2.26%)
BABA   151.37 (+0.79%)
NIO   36.70 (-0.19%)
CGC   14.71 (+0.00%)
GE   105.81 (+0.44%)
MU   74.22 (-1.28%)
AMD   106.27 (-1.75%)
T   27.66 (+0.95%)
F   14.56 (+2.82%)
ACB   6.47 (+1.25%)
DIS   177.15 (-0.62%)
PFE   42.68 (-2.04%)
BA   223.72 (-0.20%)
AMC   38.26 (-2.65%)
S&P 500   4,392.93 (-1.13%)
DOW   34,614.26 (-0.73%)
QQQ   365.06 (-1.43%)
AAPL   143.10 (-1.56%)
MSFT   289.48 (-1.59%)
FB   347.50 (-1.72%)
GOOGL   2,770.14 (-1.82%)
TSLA   788.95 (-0.30%)
AMZN   3,346.62 (-1.74%)
NVDA   211.70 (-2.26%)
BABA   151.37 (+0.79%)
NIO   36.70 (-0.19%)
CGC   14.71 (+0.00%)
GE   105.81 (+0.44%)
MU   74.22 (-1.28%)
AMD   106.27 (-1.75%)
T   27.66 (+0.95%)
F   14.56 (+2.82%)
ACB   6.47 (+1.25%)
DIS   177.15 (-0.62%)
PFE   42.68 (-2.04%)
BA   223.72 (-0.20%)
AMC   38.26 (-2.65%)
NASDAQ:BIIB

Biogen Short Interest Ratio and Short Volume

$288.31
+1.69 (+0.59 %)
(As of 09/28/2021 09:39 AM ET)
Add
Compare
Today's Range
$286.01
$290.19
50-Day Range
$286.62
$349.79
52-Week Range
$223.25
$468.55
Volume6,673 shs
Average Volume1.44 million shs
Market Capitalization$42.97 billion
P/E Ratio23.14
Dividend YieldN/A
Beta0.41

Biogen (NASDAQ:BIIB) Short Interest Data

Current Short Volume2,380,000 shares
Previous Short Volume2,180,000 shares
Change Vs. Previous Month+9.17%
Dollar Volume Sold Short$806.61 million
Short Interest Ratio / Days to Cover1.7
Last Record DateAugust, 31 2021
Outstanding Shares149,033,000 shares
Float Size148,570,000 shares
Short Percent of Float1.60%
Today's Trading Volume6,673 shares
Average Trading Volume1,439,862 shares
Today's Volume Vs. Average-99.54%

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Biogen ?

Sign up to receive the latest short interest report for Biogen and its competitors with MarketBeat's FREE newsletter.

Biogen (NASDAQ:BIIB) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/20212,380,000 shares $806.61 million +9.2%1.6%1.7 $338.91
8/13/20212,180,000 shares $746.11 million +21.8%1.5%1.1 $342.25
7/30/20211,790,000 shares $584.85 million -4.3%1.2%0.9 $326.73
7/15/20211,870,000 shares $613.66 million -2.6%1.2%1 $328.16
6/30/20211,920,000 shares $664.84 million -44.8%1.3%1 $346.27
6/15/20213,480,000 shares $1.38 billion +11.2%2.3%2 $396.08
5/28/20213,130,000 shares $837.21 million +3.0%2.1%1.9 $267.48
5/14/20213,040,000 shares $856.40 million -5.6%2.0%2.8 $281.71
4/30/20213,220,000 shares $854.36 million -0.6%2.1%2.9 $265.33
4/15/20213,240,000 shares $861.16 million -11.2%2.2%2.7 $265.79
3/31/20213,650,000 shares $1.01 billion -8.1%2.4%2.9 $276.01
3/15/20213,970,000 shares $1.06 billion +11.2%2.6%3 $266.13
2/26/20213,570,000 shares $989.82 million +4.4%2.4%2.8 $277.26
2/12/20213,420,000 shares $953.53 million -6.8%2.3%2.6 $278.81
1/29/20213,670,000 shares $983.08 million +0.8%2.4%2.4 $267.87
1/15/20213,640,000 shares $1.02 billion -2.4%2.4%2.1 $280.29
12/31/20203,730,000 shares $908.55 million -3.1%2.4%2.2 $243.58
12/15/20203,850,000 shares $944.21 million -7.0%2.5%2.3 $245.25
11/30/20204,140,000 shares $1.01 billion +11.6%2.7%2.5 $243.78
11/15/20203,710,000 shares $922.27 million -2.4%2.4%2.3 $248.59
10/30/20203,800,000 shares $932.82 million +26.3%2.5%2.5 $245.48
10/15/20203,010,000 shares $869.95 million +6.4%2.0%2.6 $289.02
9/30/20202,830,000 shares $802.81 million -23.3%1.8%2.5 $283.68
9/15/20203,690,000 shares $1.03 billion +11.5%2.3%3 $278.45
8/31/20203,310,000 shares $952.09 million +39.1%2.1%2.2 $287.64

Institutional Investors Shorting Biogen (NASDAQ:BIIB)

This table shows institutional investors, funds, and major shareholders that have reported short positions as of their most recent reporting period. Most commonly, these investors have purchased put options on shares of Biogen. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Reporting DateInvestor NameShares Shorted (Previous)Shares Shorted (Current)Position ChangePosition Size
9/13/2021Bank of America Corp DE46,100171,300+271.6%$59,316.00
8/31/2021Pathstone Family Office LLCN/A899N/A$311.00
8/20/2021Jefferies Group LLC214,60052,700-75.4%$18,248.00
8/17/2021Wells Fargo & Company MN8,00015,500+93.8%$5,367.00
8/17/2021Walleye Trading LLC34,40053,900+56.7%$18,664.00
8/17/2021Perceptive Advisors LLC600,0000-100.0%$0.00
8/17/2021Millennium Management LLC131,100262,800+100.5%$91,000.00
8/17/2021Pathstone Family Office LLCN/A899N/A$311.00
8/17/2021Parallax Volatility Advisers L.P.25,000121,600+386.4%$42,107.00
8/17/2021Atom Investors LPN/A15,900N/A$5,506.00
8/17/2021Citadel Advisors LLC896,300876,500-2.2%$303,506.00
8/16/2021Squarepoint Ops LLC23,900338,100+1,314.6%$117,074.00
8/16/2021Bank of America Corp DE46,100171,300+271.6%$59,316.00
8/16/2021SG3 Management LLC69,00066,000-4.3%$22,854.00
8/16/2021Perceptive Advisors LLC600,0000-100.0%$0.00
8/16/2021Royal Bank of Canada47,8005,900-87.7%$2,043.00
8/16/2021Credit Suisse AG126,30066,800-47.1%$23,131.00
8/16/2021Maven Securities LTD1,8000-100.0%$0.00
8/16/2021Jefferies Group LLC214,6005,270,000+2,355.7%$18,248.00
8/16/2021Goldman Sachs Group Inc.20,00050,000+150.0%$17,314.00
8/16/2021Allianz Asset Management GmbH9002,600+188.9%$900.00
8/13/2021PEAK6 Investments LLC234,600262,700+12.0%$90,965.00
8/12/2021SG Americas Securities LLC10,00052,000+420.0%$880.00
8/12/2021Simplex Trading LLC1,0530-100.0%$0.00
8/12/2021JPMorgan Chase & Co.10,00062,300+523.0%$21,573.00
8/12/2021Twin Tree Management LP67,60050,400-25.4%$17,452.00
8/11/2021HAP Trading LLC40,10039,600-1.2%$495.00
8/11/2021Susquehanna International Group LLP1,193,7001,191,700-0.2%$412,650.00
8/10/2021BNP Paribas Arbitrage SA394844+114.2%$29,225.00
8/6/2021Wolverine Trading LLC82,200117,700+43.2%$40,691.00
8/6/2021IMC Chicago LLC52,800241,800+358.0%$83,728.00
8/3/2021Avestar Capital LLCN/A3,200N/A$1,108.00
7/31/2021Cutler Group LP11,7004,700-59.8%$100.00
7/26/2021XR Securities LLC9,7006,100-37.1%$227.00

Biogen (NASDAQ:BIIB) Short Interest FAQ

speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Short Interest Frequently Asked Questions

What is Biogen's current short interest?

Short interest is the volume of Biogen shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 2,380,000 shares of BIIB short. 1.60% of Biogen's shares are currently sold short. Learn More on Biogen's current short interest.

What is a good short interest ratio for Biogen?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Biogen currently has a short interest ratio of 2.0. Learn More on a good short interest ratio for Biogen

Which institutional investors are shorting Biogen?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Biogen: Bank of America Corp DE, Pathstone Family Office LLC, Jefferies Group LLC, Wells Fargo & Company MN, Walleye Trading LLC, Perceptive Advisors LLC, Millennium Management LLC, Pathstone Family Office LLC, Parallax Volatility Advisers L.P., Atom Investors LP, Citadel Advisors LLC, Squarepoint Ops LLC, Bank of America Corp DE, SG3 Management LLC, Perceptive Advisors LLC, Royal Bank of Canada, Credit Suisse AG, Maven Securities LTD, Jefferies Group LLC, Goldman Sachs Group Inc., Allianz Asset Management GmbH, PEAK6 Investments LLC, SG Americas Securities LLC, Simplex Trading LLC, JPMorgan Chase & Co., Twin Tree Management LP, HAP Trading LLC, Susquehanna International Group LLP, BNP Paribas Arbitrage SA, Wolverine Trading LLC, IMC Chicago LLC, Avestar Capital LLC, Cutler Group LP, and XR Securities LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Biogen?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.60% of Biogen's floating shares are currently sold short.

Is Biogen's short interest increasing or decreasing?

Biogen saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,380,000 shares, an increase of 9.2% from the previous total of 2,180,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Biogen's float size?

Biogen currently has issued a total of 149,033,000 shares. Some of Biogen's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Biogen currently has a public float of 148,570,000 shares.

How does Biogen's short interest compare to its competitors?

1.60% of Biogen's shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Biogen: Amgen Inc. (1.98%), Gilead Sciences, Inc. (0.00%), Regeneron Pharmaceuticals, Inc. (1.33%), Vertex Pharmaceuticals Incorporated (1.87%), Seagen Inc. (1.45%), Alnylam Pharmaceuticals, Inc. (0.00%), Novavax, Inc. (8.25%), Exact Sciences Co. (0.00%), Repligen Co. (3.08%), and Incyte Co. (2.72%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Square, Inc. ($9.81 billion), S&P Global Inc. ($7.52 billion), Advanced Micro Devices, Inc. ($7.18 billion), Charter Communications, Inc. ($6.21 billion), Wayfair Inc. ($4.60 billion), Zoom Video Communications, Inc. ($3.23 billion), Uber Technologies, Inc. ($3.11 billion), Palo Alto Networks, Inc. ($2.74 billion), Teladoc Health, Inc. ($2.52 billion), and Etsy, Inc. ($2.16 billion). View all of the most shorted stocks.

What does it mean to sell short Biogen stock?

Short selling BIIB is an investing strategy that aims to generate trading profit from Biogen as its price is falling. Biogen's stock is trading up $1.69 today. To short Biogen stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Biogen will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Biogen?

A short squeeze for Biogen occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BIIB, which in turn drives the price of the stock up even further.

How often is Biogen's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BIIB, twice per month. The most recent reporting period available is August, 31 2021.



This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.